### Check for updates

#### **OPEN ACCESS**

EDITED BY Ningning Hou, Affiliated Hospital of Weifang Medical University, China

REVIEWED BY Josef Fritz, Innsbruck Medical University, Austria Antonio Junior Lepedda, University of Sassari, Italy

\*CORRESPONDENCE Lianglong Chen Chen19720000@163.com Quanzhong Hu Qinghaihospital@126.com

<sup>†</sup>These authors have contributed equally to this work

#### SPECIALTY SECTION

This article was submitted to Renal Endocrinology, a section of the journal Frontiers in Endocrinology

RECEIVED 07 September 2022 ACCEPTED 02 December 2022 PUBLISHED 14 December 2022

#### CITATION

Dong J, Yang H, Zhang Y, Chen L and Hu Q (2022) A high triglyceride glucose index is associated with early renal impairment in the hypertensive patients. *Front. Endocrinol.* 13:1038758. doi: 10.3389/fendo.2022.1038758

#### COPYRIGHT

© 2022 Dong, Yang, Zhang, Chen and Hu. This is an open-access article distributed under the terms of the **Creative Commons Attribution License** (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# A high triglyceride glucose index is associated with early renal impairment in the hypertensive patients

Jiankai Dong <sup>1†</sup>, Huijie Yang<sup>2†</sup>, Yaping Zhang<sup>2</sup>, Lianglong Chen<sup>1\*</sup> and Quanzhong Hu<sup>2\*</sup>

<sup>1</sup>Department of Cardiology, Fujian Medical University Union Hospital, Fujian Cardiovascular Medical Center, Fujian Institute of Coronary Heart Disease, Fuzhou, China, <sup>2</sup>Department of Cardiology, Qinghai Provincial People's Hospital, Xining, China

**Objective:** Serum  $\beta$ 2-microglobulin ( $\beta$ 2-MG) and serum cystatin C (CysC) are sensitive and reliable indicators of early renal impairment. Triglyceride glucose index (TyG) is an emerging vital indicator of insulin resistance and is associated with increased risk of hypertension. We aimed to analyze the relationship between TyG and early renal impairment in hypertensive patients.

Methods: A retrospective analysis was performed on 881 hypertensive patients treated in Qinghai Provincial People, s Hospital from March 2018 to March 2021, their clinical data and corresponding laboratory index values were recorded, and the TyG index was calculated. According to the TyG index, the patients were divided into a low TyG (L-TyG) group (TyG < 8.50, n=306), medium TyG (M-TyG) group ( $8.51 \le TyG \le 8.94$ , n=281), and high TyG (H-TyG) group (TyG>8.95, n=294) in sequence by using tertiles. Then, according to serum  $\beta$ 2-MG and CysC levels, they were divided into a normal renal function group ( $\beta$ 2-MG  $\leq$  2.4 mg/L, n=700 and CysC  $\leq$  1.25mg/L, n=721) and a renal function injury group ( $\beta$ 2-MG>2.4 mg/L, n=181, and CysC>1.25 mg/L, n=160). Multivariate linear regression analysis was used to analyze the influencing factors of serum β2-microglobulin and cystatin C. Multivariate Logistic regression was used to analyze the relationship between the TyG index and early renal impairment in hypertensive patients. The receiver operating characteristic curve (ROC) was used to determine the value of the TyG index in predicting early renal impairment in patients with hypertension.

**Result:** As the TyG index level increased, serum  $\beta$ 2-MG and CysC levels also gradually increased. Multivariate linear regression analysis showed that TyG index was the influencing factor of serum  $\beta$ 2-MG (B=0.060, P=0.007) and serum CysC (B=0.096, P<0.001). For every 1 standard deviation increase in the TyG index, the serum  $\beta$ 2-MG and CysC increased by 0.06mg/L and 0.096mg/L, respectively. When compared to the normal group, the TyG level (8.91 ± 0.65 vs 8.64 ± 0.60, P<0.001) was higher in the renal impairment group with  $\beta$ 2-MG>2.4 mg/L. The results of multivariate logistic regression analysis revealed that for every 1 standard deviation increase in the TyG index, the risk of early

renal impairment in hypertensive patients increased 1.53 times (OR=1.53, 95% CI 1.006-2.303). The ROC curves showed that the TyG index was not superior to TG in predicting early renal impairment in hypertensive patients. the AUC values were 0.623 and 0.617, respectively. Then, when CysC>1.25 mg/L was used as the renal damage group, the level of TyG was still higher than that in the normal group (8.94  $\pm$  0.67 and 8.64  $\pm$  0.60, P<0.001). Multivariate Logistic regression analysis showed that for every 1 standard deviation increase in the TyG index, the risk of early renal impairment in hypertensive patients increased 2.82 times (OR=2.82, 95%CI 1.863-4.262). The ROC curves showed that the TyG index was not superior to TG in predicting early renal impairment in hypertensive patients.

**Conclusion:** TyG index is an influential factor in serum  $\beta$ 2-MG and CysC levels. The elevated TyG index levels are closely associated with the occurrence and development of early renal impairment in hypertensive patients, but it should be used cautiously in the prediction of early renal impairment.

### KEYWORDS

hypertension, triglyceride glucose index, insulin resistance, renal impairment,  $\beta 2$  microglobulin, Urine microalbumin, cystatin C

### 1 Introduction

With an aging population, hypertension has become the most important risk factor for cardiovascular disease morbidity and mortality (1). In addition, hypertension is a long-term progressive chronic disease, and renal injury is its major complication. Currently, serum urea nitrogen, serum creatinine (SCr) and glomerular filtration rate (GFR) are widely used clinically to evaluate renal function. but the diagnostic specificity is low due to the high storage capacity of the kidney and the influence of drugs, age and glomerular filtration rate. Studies have shown that urine microalbumin, serum  $\beta$ 2-microglobulin ( $\beta$ 2-MG) and serum cystatin C (CysC) are sensitive and reliable indicators of early renal injury, and their sensitivity and specificity are higher than those of serum urea nitrogen and serum creatinine (2, 3).

Insulin resistance (IR) is common in patients with hypertension (4), and IR is strongly associated with the prevalence of chronic renal insufficiency (5). A recent study found that the triglyceride-glucose index (TyG index) derived from the log- transformation of the product of plasma triglyceride (TG) and fasting plasma glucose (FPG) was a potential IR marker (6, 7). It has been shown that an elevated TyG index is associated with the occurrence and development of atherosclerosis (8), coronary artery disease (8), hypertension (9), diabetes (10), Diabetic kidney disease (11), nonalcoholic fatty liver (12), and nephric microvascular damage (13), etc. However, there are few reports on the relationship

between the TyG index and early renal injury in hypertensive patients at home and abroad.

Therefore, this study aimed to investigate the correlation between the TyG index and early renal impairment in hypertensive patients, to provide a reference basis for the early prevention, monitoring, and treatment of chronic kidney disease (CKD).

### 2 Patients & methods

### 2.1 Study population

A total of 881 inpatients with primary hypertension from March 2018 to March 2021 in Qinghai Provincial People's Hospital were included as the subjects, including 464 males and 417 females, aged from 40 to 92 years old, with an average age of  $(60.06 \pm 12.23)$  years old.

Inclusion criteria: ① Age≥40 years old, no sex limitation, and complete clinical data. ② Hypertension was defined as having two independent blood pressure measurements≥140/90mmHg or having received antihypertensive drug treatment.③ eGFR≥60 ml/min/1.73m<sup>2</sup>.

Exclusion criteria: secondary hypertension, coronary atherosclerotic heart disease, heart failure, diabetes; Various acute and chronic infectious diseases, primary glomerular disease, renal artery stenosis; Patients with severe liver and kidney function impairment; Thyroid disease, malignant tumor, clear familial hyperlipidemia, and lipid-lowering drugs in the past 1 month; Cognitive dysfunction, mental illness. The study protocol was approved by the Ethics Committee of Qinghai Provincial People's Hospital. All participants signed the informed consent.

### 2.2 Data collection

Clinical data such as sex, age, body weight, smoking history, and duration of hypertension of the subjects were accurately recorded, and body mass index (BMI) was calculated as follows.

 $BMI = body mass(kg)/height(m)^2$ 

All subjects fasted for 10-12 hours one day before the experiment, 4-5 mL venous blood were drawn next morning, and the serum was collected after centrifugation at 4 000 r/min. The fasting plasma glucose (FPG) was measured by the glucose oxidase method. Triglyceride (TG), urea nitrogen (BUN), serum creatinine (Scr), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and serum uric acid (SUA) were measured by enzyme method. Serum  $\beta$ 2-microglobulin (0.8-2.4mg/L) was determined by ELISA, and cystatin C (0.54-1.25mg/L) was determined by latex nephelometry. The above indexes were performed with a Beckman AU5800 automatic biochemical analyzer. The estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI formula.

### 2.3 Groups

TyG index (6)=Ln[fasting TG (mg/dL)×FBG (mg/dL)/2], where TG (1mg/dL=0.011mmol/L) and FBG (1mg/ dL=0.056mmol/L). According to the TyG index, patients were divided into a low TyG (L-TyG) group (TyG  $\leq$  8.50, n=306), medium TyG (M-TyG) group (8.51 $\leq$ TyG  $\leq$  8.94, n=281) and high TyG (H-TyG) group (TyG>8.95, n=294) in sequence by using tertiles. In addition, 881 hypertensive patients were divided into a normal renal function group (serum  $\beta$ 2-MG  $\leq$ 2.4 mg/L and CysC  $\leq$  1.25mg/L) and an impaired renal function group (serum  $\beta$ 2-MG>2.4 mg/L and CysC>1.25 mg/L) according to serum  $\beta$ 2-MG and CysC levels.

### 24 Statistical analysis

Statistical analysis was performed using SPSS 26.0 (SPSS Inc.). The single-sample k-s test (two-sided test) was used to test whether the measurement data conformed to a normal distribution. Measurement data of normal distribution are

expressed as the mean ± standard deviation. Student's t-test was used for comparisons between two groups, a one-way analysis of variance was used for comparisons among three groups, and the LSD test was used for pairwise comparisons between groups. The measurement data with a nonnormal distribution are expressed as M(Q25, Q75). Means of 2 groups were compared using the Mann-Whitney U test. Multiple-group comparisons were made by Kruskal-Wallis tests. Enumeration data were compared using the X<sup>2</sup> test. Multifactor linear stepwise regression was used to analyze the influencing factors of serum β2- microglobulin and cystatin C. Logistic regression analysis was used to analyze the influencing factors of early renal impairment in patients with hypertension. The receiver operating characteristic curve (ROC) was used to determine the value of the TyG index in predicting early renal impairment in patients with hypertension. P<0.05 was considered statistically significant.

### **3** Results

# 3.1 Comparison of general data and clinical indicators among three groups of TyG index

A total of 881 patients (mean age  $60.06 \pm 12.23$  years, 464 men) with hypertension were included in the study. The baseline clinical characteristics and laboratory measurements of patients within the groups are presented in Table 1. Participants were grouped into tertiles according to their TyG level. There were no significant differences among the three groups in sex, smoking history, BMI, hypertension course, HS-CRP, mALB, BUN and eGFR levels (P>0.05). The levels of TC, HDL-C, LDL-C, Alb, TG, FBG,  $\beta$ 2-MG, CysC and SUA were compared and the differences were statistically different (P<0.05, as shown in Table 1). Besides, the levels of  $\beta$ 2-MG (1.96 ± 0.82) and CysC  $(1.04 \pm 0.27)$  in the M-TyG group were significantly higher than that in the L-TyG group (1.87  $\pm$  0.65 and 1.03  $\pm$  0.44). The levels in the H-TyG group (2.29  $\pm$  1.04 and 1.18  $\pm$  0.44) were significantly higher than that in the M-TyG group (1.96  $\pm$  0.82 and  $1.04 \pm 0.27$ ).

### 3.2 Multivariate linear regression analysis

The relationship between the TyG index and early renal injury indicators was analyzed by Multivariate linear regression with serum  $\beta$ 2-MG and serum cystatin C as dependent variables and age, BMI, TC, hypertension course, LDL-C, Alb, HS-CRP, HDL-C, eGFR, SUA, TyG index, BUN, mALB and Sex as independent variables. The results showed that the TyG index level was an influencing factor of serum  $\beta$ 2-MG (B=0.060, 95%)

|                              | L-TyG group (n=306)  | M-TyG group (n=281)  | H-TyG group (n=294)      | P value |
|------------------------------|----------------------|----------------------|--------------------------|---------|
| Male [n,(%)]                 | 175 (57.2%)          | 135 (48.0%)          | 155 (52.7%)              | 0.086   |
| Smoking history [, (%)]      | 64 (20.9%)           | 54 (19.2%)           | 80 (27.2)                | 0.052   |
| Age (y)                      | 62.00 ± 12.92        | 60.53 ± 11.85        | $57.61 \pm 11.47^{ab}$   | < 0.001 |
| BMI (kg/m2)                  | 25.09 ± 4.11         | 25.59 ± 3.79         | 25.64 ± 3.62             | 0.153   |
| hypertension course (months) | 60.00 (36.00-120.00) | 60.00 (24.00-120.00) | 54.00 (24.00-120.00)     | 0.103   |
| TC (mmol/l)                  | 3.97 ± 0.89          | $4.32 \pm 0.83^{a}$  | $4.38 \pm 2.22^{ab}$     | < 0.001 |
| HDL-C (mmol/L)               | 1.11 ± 0.29          | $1.05 \pm 0.22^{a}$  | $0.97 \pm 0.20^{ab}$     | < 0.001 |
| LDL-C (mmol/L)               | $2.40 \pm 0.74$      | $2.68 \pm 0.70^{a}$  | $2.72 \pm 0.77^{a}$      | < 0.001 |
| Alb (mg/L)                   | 39.05 ± 4.24         | $40.22 \pm 3.86^{a}$ | $40.88 \pm 3.93^{a}$     | < 0.001 |
| Scr (µmol/L)                 | $68.48 \pm 14.17$    | 69.57 ± 13.64        | $71.59 \pm 14.93^{a}$    | 0.026   |
| eGFR[ml.min-1.(1.73m2)-1]    | 94.96 ± 16.13        | 92.68 ± 16.64        | 92.93 ± 17.76            | 0.179   |
| HS-CRP (mg/dl)               | 0.13 (0.06-0.33)     | 0.14 (0.06-0.29)     | 0.15 (0.08-0.30)         | 0.465   |
| BUN (mmol/L)                 | 5.75 ± 1.67          | 5.49 ± 1.51          | 5.57 ± 1.42              | 0.138   |
| SUA (µmol/L)                 | 347.54 ± 109.99      | 358.45 ± 96.54       | $385.25 \pm 104.74^{ab}$ | < 0.001 |
| TG (mmol/L)                  | 0.92 ± 0.29          | $1.63 \pm 0.32^{a}$  | $2.99 \pm 0.84^{ab}$     | < 0.001 |
| FBG (mmol/L)                 | $4.50 \pm 0.61$      | $4.78 \pm 0.56^{a}$  | $5.20 \pm 0.53^{ab}$     | < 0.001 |
| mALB (mg/L)                  | 1.00 (0.59-2.45)     | 1.06 (0.61-2.16)     | 1.11 (0.59-2.36)         | 0.957   |
| β2-MG (mg/L)                 | $1.87 \pm 0.65$      | 1.96 ± 0.82          | $2.29 \pm 1.04^{ab}$     | < 0.001 |
| CysC (mg/L)                  | $1.03 \pm 0.44$      | $1.04 \pm 0.27$      | $1.18 \pm 0.44^{ab}$     | < 0.001 |

TABLE 1 Comparison of general data and clinical indicators of the L-TyG group, M-TyG group, and H-TyG.

Data are expressed as the mean  $\pm$  SD, median (25th–75th percentiles), or number (percentage). BMI, body mass index; Fib, fibrinogen; TC, cholesterol; HDL-C, high-density lipoprotein cholesterol level; Alb, albumin; Scr, serum creatinine; eGFR, estimated glomerular filtration rate; HS-CRP, high-sensitivity C-reactive protein; BUN, Blood Urea Nitrogen; SUA, Serum uric acid; TG, triglyceride; FBG, fasting blood-glucose; mALB, urine microalbumin;  $\beta$ 2-MG, serum  $\beta$ 2 microglobulin; CysC, Serum cystatin C.

a' p < 0.05 compared with the L-TyG group; p<0.01 compared with the M-TyG group.

CI 0.017-0.103, P=0.007) and CysC (B=0.096, 95%CI 0.055-0.137, P<0.001). For every 1 standard deviation increase in the TyG index, the serum  $\beta$ 2-MG and CysC increased by 0.06mg/L and 0.096mg/L, respectively (Table 2).

# 3.3 Comparison of general data and clinical index between two groups on $\beta$ 2-MG level

Patients were divided into a normal renal function group ( $\beta$ 2-MG  $\leq$  2.4 mg/L) and an impaired renal function group ( $\beta$ 2-MG>2.4 mg/L) according to  $\beta$ 2-MG level. The age of patients in the renal impairment group ( $66.54 \pm 12.19$ ) was significantly higher than that in the normal renal function group ( $58.40 \pm 11.69$ , P<0.001), and there was no significant difference in the levels of sex, smoking history, BMI, TC, LDL-C or mALB between the two groups (P>0.05). The levels of hypertension course, Scr, HS-CRP, BUN, SUA, TG and TyG index in the renal function injury group were significantly higher than those in the normal renal function

group. HDL-C, Alb, and eGFR levels were significantly lower than those in the normal renal function group, and the differences were statistically significant (P<0.05, see Table 3).

# 3.4 Comparison of general data and clinical index between two groups on the level of CysC

Patients were divided into a normal renal function group (CysC  $\leq$  1.25 mg/L) and an impaired renal function group (CysC>1.25 mg/L) according to CysC level. There was no significant difference in the levels of sex, BMI, TC, HDL-C, LDL-C or mALB levels between the two groups (P>0.05). The levels of age, hypertension course, Scr, HS-CRP, BUN, SUA, TG, and TyG index in the renal impairment group were significantly higher than those in the normal renal function group. The smoking history, Alb, and eGFR levels were significantly lower than those in the normal renal function group, and the differences were statistically significant (P<0.05, see Table 4).

| Dependent variable | Independent variable | В      | SE    | Beta   | t      | P value | 95% Cl           |
|--------------------|----------------------|--------|-------|--------|--------|---------|------------------|
| β2-MG              | Age                  | 0.004  | 0.001 | 0.113  | 2.811  | 0.005   | (0.001, 0.006)   |
|                    | BMI                  | 0.005  | 0.003 | 0.047  | 1.519  | 0.129   | (-0.001, 0.011)  |
|                    | hypertension course  | 0.001  | 0.002 | 0.01   | 0.307  | 0.759   | (-0.003, 0.004)  |
|                    | TC                   | 0.01   | 0.006 | 0.057  | 1.794  | 0.073   | (-0.001, 0.022)  |
|                    | LDL-C                | -0.007 | 0.018 | -0.014 | -0.414 | 0.679   | (-0.042, 0.027)  |
|                    | mALB                 | 0      | 0.001 | 0.011  | 0.348  | 0.728   | (-0.002, 0.003)  |
|                    | eGFR                 | -0.006 | 0.001 | -0.262 | -6.508 | < 0.001 | (-0.008, -0.004) |
|                    | Alb                  | -0.006 | 0.003 | -0.058 | -1.73  | 0.084   | (-0.012, 0.001)  |
|                    | HS-CRP               | 0.083  | 0.017 | 0.152  | 4.91   | < 0.001 | (0.05, 0.117)    |
|                    | SUA                  | 0.001  | 0     | 0.136  | 3.671  | < 0.001 | (0, 0.001)       |
|                    | BUN                  | 0.007  | 0.009 | 0.026  | 0.793  | 0.428   | (-0.01, 0.024)   |
|                    | HDL-C                | -0.132 | 0.055 | -0.082 | -2.399 | 0.017   | (-0.24, -0.024)  |
|                    | TyG index            | 0.060  | 0.022 | 0.092  | 2.714  | 0.007   | (0.017, 0.103)   |
|                    | Sex (Male)           | 0.071  | 0.029 | 0.088  | 2.408  | 0.016   | (0.013, 0.129)   |
| CysC               | Age                  | 0.003  | 0.001 | 0.095  | 2.357  | 0.019   | (0, 0.005)       |
|                    | BMI                  | -0.003 | 0.003 | -0.034 | -1.102 | 0.271   | (-0.009, 0.003)  |
|                    | hypertension course  | 0.001  | 0.002 | 0.018  | 0.542  | 0.588   | (-0.003, 0.004)  |
|                    | TC                   | -0.008 | 0.006 | -0.046 | -1.422 | 0.155   | (-0.019, 0.003)  |
|                    | LDL-C                | 0.012  | 0.017 | 0.023  | 0.71   | 0.478   | (-0.021, 0.045)  |
|                    | mALB                 | 0.003  | 0.001 | 0.075  | 2.461  | 0.014   | (0.001, 0.005)   |
|                    | eGFR                 | -0.006 | 0.001 | -0.256 | -6.342 | < 0.001 | (-0.008, -0.004  |
|                    | Alb                  | -0.008 | 0.003 | -0.087 | -2.591 | 0.010   | (-0.014, -0.002  |
|                    | HS-CRP               | 0.046  | 0.016 | 0.088  | 2.836  | 0.005   | (0.014, 0.078)   |
|                    | SUA                  | 0      | 0     | 0.131  | 3.529  | < 0.001 | (0, 0.001)       |
|                    | BUN                  | 0.019  | 0.008 | 0.075  | 2.252  | 0.025   | (0.002, 0.035)   |
|                    | HDL-C                | 0.058  | 0.053 | 0.038  | 1.11   | 0.267   | (-0.045, 0.162)  |
|                    | TyG index            | 0.096  | 0.021 | 0.155  | 4.545  | < 0.001 | (0.055, 0.137)   |
|                    | Sex(Male)            | -0.054 | 0.028 | -0.07  | -1.913 | 0.056   | (-0.109, 0.001)  |

### TABLE 2 Multivariate linear regression analysis.

### 3.5 Multi-factor logistic regression analysis of influencing factors of early renal impairment in patients with hypertension

Taking the occurrence of renal impairment ( $\beta$ 2-MG>2.4 mg/L) as the dependent variable, and taking age, BMI, total cholesterol, hypertension course, LDL-C, Alb, HS-CRP, HDL-C, eGFR, SUA, TyG index, BUN, mALB, and Sex as the independent variables, a multivariate Logistic regression analysis was performed. The results showed that age

(OR=1.03, 95%CI 1.011-1.055, P=0.003), TyG index (OR=1.53, 95%CI 1.008-2.319, P=0.046), HS-CRP (OR=1.81, 95%CI 1.349-2.415, P<0.001), SUA (OR=1.01, 95%CI 1.002-1.006, P=0.001), HDL-C (OR=0.29, 95%CI 1.349-2.415, P=0.014), eGFR (OR=0.95, 95%CI 0.932-0.964, P<0.001) and Male (OR=0.62, 95%CI 0.385-0.989, P=0.045), these were the risk factors for early renal impairment in patients with hypertension (P<0.05, see Table 5).

Then, renal impairment (CysC>1.25mg/L) was used as the dependent variable. A multivariate Logistic regression analysis was performed. The results showed that age (OR=1.04, 95%CI

|                              | Normal renal function group (n=700) | Impaired renal function group (n=181) | P value |
|------------------------------|-------------------------------------|---------------------------------------|---------|
| Male [n,(%)]                 | 380 (54.3%)                         | 85 (47.0%)                            | 0.079   |
| Smoking history [n, (%)]     | 163 (23.3%)                         | 35 (19.3%)                            | 0.257   |
| Age (y)                      | $58.40 \pm 11.69$                   | $66.54 \pm 12.19$                     | < 0.001 |
| BMI(kg/m2)                   | 25.31 ± 3.71                        | 25.93 ± 4.36                          | 0.084   |
| hypertension course (months) | 48.00 (24.00-120.00)                | 84.00 (36.00-132.00)                  | 0.001   |
| TC (mmol/l)                  | $4.30 \pm 0.89$                     | 4.72 ± 4.57                           | 0.219   |
| HDL-C (mmol/L)               | $1.06 \pm 0.24$                     | 0.99 ± 0.29                           | 0.001   |
| LDL-C (mmol/L)               | 2.59 ± 0.73                         | 2.62 ± 0.83                           | 0.640   |
| Alb (mg/L)                   | $40.40 \pm 3.96$                    | 38.63 ± 4.30                          | < 0.001 |
| Scr (µmol/L)                 | 68.32 ± 13.63                       | 75.87 ± 15.31                         | < 0.001 |
| eGFR [ml.min-1.(1.73m2)-1]   | 96.91 ± 15.58                       | 80.60 ± 15.35                         | < 0.001 |
| HS-CRP (mg/dl)               | 0.12 (0.06-0.26)                    | 0.24 (0.11-0.56)                      | < 0.001 |
| BUN (mmol/L)                 | $5.48 \pm 1.46$                     | 6.12 ± 1.77                           | < 0.001 |
| SUA (µmol/L)                 | 353.31 ± 96.08                      | $403.43 \pm 127.48$                   | < 0.001 |
| TG (mmol/L)                  | $1.75 \pm 0.96$                     | $2.22 \pm 1.18$                       | < 0.001 |
| FBG (mmol/L)                 | $4.79 \pm 0.65$                     | $4.97 \pm 0.58$                       | 0.001   |
| TyG index                    | $8.64\pm0.60$                       | 8.91 ± 0.65                           | < 0.001 |
| mALB (mg/dl)                 | 1.01 (0.60-2.07)                    | 1.19 (0.63-3.22)                      | 0.051   |

TABLE 3 Comparison of general data and clinical index between two groups on β2-MG level.

Data are expressed as the mean ± SD, median (25th-75th percentiles), or number (percentage). TyG index, Triglyceride glucose index

1.015-1.062, P=0.001), TyG index (OR=2.98, 95%CI 1.954-4.535, P<0.001), HS-CRP (OR=1.40, 95%CI 1.095-1.792, P=0.007), SUA (OR=1.01, 95%CI 1.001-1.006, P=0.002), Alb (OR=0.93, 95%CI 0.871-0.985, P=0.015), eGFR (OR=0.95, 95% CI 0.938-0.970, P<0.001) and Male (OR=1.88, 95%CI 1.114-3.038, P=0.013), these were the risk factors for early renal impairment in patients with hypertension (P<0.05, see Table 6).

# 3.6 ROC curve of TyG index in predicting early renal impairment in hypertensive patients

The ROC curve of the TyG index predicting early renal impairment in hypertensive patients was further drawn. The renal impairment was defined as  $\beta$ 2-MG > 2.4 mg/L. The results showed that the area under the ROC curve of the TyG index in predicting early renal impairment in hypertensive patients was 0.623 (P<0.001; 95%CI0.574-0.671), when the TyG index is 9.205, the Jouden index is 0.225, the sensitivity is 39.2%, and the specificity is 83.3%. The AUC of the FPG and TG levels for predicting early renal impairment occurs in hypertensive patients was 0.573 (95%CI 0.528-0.618, P=0.002) and 0.617 (95%CI 0.569-0.665, P<0.001), respectively (Figure 1).

Then with CysC>1.25 mg/L as the occurrence of renal impairment, the ROC curve of the TyG index predicting early renal impairment in hypertensive patients was also drawn, and the area under the curve was 0.629 (P<0.001; 95%CI 0.577-0.681), when the TyG index is 9.315, the maximum Jouden index is 0.266, the sensitivity is 38.8%, and the specificity is 87.8%. The AUC of the FPG and TG levels for predicting early renal impairment occurs in hypertensive patients was 0.570 (95%CI 0.522-0.619, P=0.005) and 0.626 (95%CI 0.574-0.678, P<0.001), respectively (Figure 2).

## 4 Discussion

This study investigated the relationship between the TyG index and early renal impairment in hypertensive patients. The results of Multivariate linear regression analysis showed that the level of TyG index was an influencing factor of serum  $\beta$ 2-MG and CysC. Logistic regression analysis showed that the relative risk of developing renal impairment was higher in patients with elevated TyG index, suggesting that the TyG index was significantly associated with early renal impairment in hypertensive patients.

CKD is associated with increased mortality, and one of the factors contributing to increased mortality is IR. IR is present in

|   | Normal renal function group (n=721) | Impaired renal function group (n=160) | P value |
|---|-------------------------------------|---------------------------------------|---------|
| Male [n,(%)]  | 369 (51.2%)                         | 95 (59.4%)                            | 0.063   |
| Smoking history [n, (%)]  | 150 (20.8%)                         | 47 (29.4%)                            | 0.019   |
| Age (y)   | 58.55 ± 11.74                       | 66.94 ± 12.12                         | < 0.001 |
| BMI (kg/m <sup>2</sup> )  | 25.43 ± 3.72                        | $25.47 \pm 4.45$                      | 0.927   |
| hypertension course(months)                                       | 54.00 (24.00-120.00)                | 72.00 (36.00-153.00)                  | 0.001   |
| TC (mmol/l)   | 4.39 ± 2.40                         | $4.39 \pm 1.07$                       | 0.996   |
| HDL-C (mmol/L)  | $1.06 \pm 0.25$                     | $1.02 \pm 0.26$                       | 0.122   |
| LDL-C (mmol/L)  | 2.59 ± 0.73                         | 2.65 ± 0.83                           | 0.395   |
| Alb (mg/L)  | 40.38 ± 3.95                        | $38.50 \pm 4.38$                      | < 0.001 |
| Scr (µmol/L)  | 67.78 ± 13.83                       | 79.25 ± 12.68                         | < 0.001 |
| eGFR [ml.min <sup>-1</sup> .(1.73m <sup>2</sup> ) <sup>-1</sup> ] | 96.61 ± 15.85                       | $79.72 \pm 14.21$                     | < 0.001 |
| HS-CRP (mg/dl)  | 0.13 (0.06-0.28)                    | 0.22 (0.10-0.52)                      | < 0.001 |
| BUN (mmol/L)  | $5.44 \pm 1.44$                     | 6.39 ± 1.75                           | < 0.001 |
| SUA (µmol/L)  | 352.42 ± 97.91                      | $414.28 \pm 121.40$                   | < 0.001 |
| TG (mmol/L)   | $1.74 \pm 0.94$                     | $2.32 \pm 1.26$                       | < 0.001 |
| FBG (mmol/L)  | $4.80 \pm 0.63$                     | $4.95 \pm 0.65$                       | 0.008   |
| TyG index   | $8.64 \pm 0.60$                     | 8.94 ± 0.67                           | < 0.001 |
| mALB (mg/L)   | 1.03 (0.60-2.10)                    | 1.18 (0.63-3.52)                      | 0.107   |

### TABLE 4 Comparison of general data and clinical index between two groups on the CysC level.

TABLE 5 Multivariate Logistic regression analysis of early renal impairment (β2-MG>2.4mg/L) in hypertensive patients.

|                               | β      | SE    | Wald X <sup>2</sup> value | P value | OR value | 95%Cl          |
|-------------------------------|--------|-------|---------------------------|---------|----------|----------------|
| Age                           | 0.032  | 0.011 | 8.689                     | 0.003   | 1.03     | (1.011, 1.055) |
| BMI                           | 0.046  | 0.026 | 3.163                     | 0.075   | 1.05     | (0.995, 1.101) |
| hypertension course           | 0      | 0.014 | 0.001                     | 0.973   | 1        | (0.974, 1.027) |
| TyG index                     | 0.425  | 0.212 | 3.994                     | 0.046   | 1.53     | (1.008, 2.319) |
| TC                            | 0.486  | 0.251 | 3.747                     | 0.053   | 1.63     | (0.994, 2.659) |
| LDL-C                         | -0.479 | 0.284 | 2.837                     | 0.092   | 0.62     | (0.355, 1.082) |
| Alb                           | -0.051 | 0.030 | 2.866                     | 0.090   | 0.95     | (0.896, 1.008) |
| HS-CRP                        | 0.590  | 0.149 | 15.800                    | < 0.001 | 1.81     | (1.349, 2.415) |
| HDL-C                         | -1.243 | 0.506 | 6.037                     | 0.014   | 0.29     | (0.107, 0.778) |
| eGFR                          | -0.054 | 0.008 | 39.900                    | < 0.001 | 0.95     | (0.932, 0.964) |
| SUA                           | 0.004  | 0.001 | 11.153                    | 0.001   | 1.01     | (1.002, 1.006) |
| BUN                           | 0.015  | 0.070 | 0.045                     | 0.832   | 1.02     | (0.885, 1.163) |
| mALB                          | 0.001  | 0.008 | 0.007                     | 0.932   | 1.00     | (0.986, 1.105) |
| Sex (Male)                    | -0.482 | 0.241 | 4.019                     | 0.045   | 0.62     | (0.385, 0.989) |
| Abbreviations as given in Tal | ble 1. |       |                           |         |          |                |

|                     | β      | SE    | Wald X <sup>2</sup> value | P value | OR value | 95%Cl          |
|---------------------|--------|-------|---------------------------|---------|----------|----------------|
| Age                 | 0.038  | 0.012 | 10.387                    | 0.001   | 1.04     | (1.015, 1.062) |
| BMI                 | -0.19  | 0.028 | 0.462                     | 0.497   | 0.99     | (0.929, 1.036) |
| hypertension course | 0.004  | 0.014 | 0.080                     | 0.778   | 1.01     | (0.977, 1.032) |
| TyG index           | 1.091  | 0.215 | 25.774                    | < 0.001 | 2.98     | (1.954, 4.535) |
| TC                  | -0.061 | 0.094 | 0.418                     | 0.518   | 0.94     | (0.782, 1.132) |
| LDL-C               | 0.080  | 0.174 | 0.214                     | 0.644   | 1.09     | (0.771, 1.524) |
| Alb                 | -0.076 | 0.032 | 5.884                     | 0.015   | 0.93     | (0.871, 0.985) |
| HS-CRP              | 0.337  | 0.126 | 7.197                     | 0.007   | 1.40     | (1.095, 1.792) |
| HDL-C               | 0.683  | 0.457 | 2.235                     | 0.135   | 1.98     | (0.809, 4.846) |
| eGFR                | -0.048 | 0.009 | 31.172                    | < 0.001 | 0.95     | (0.938, 0.970) |
| SUA                 | 0.004  | 0.001 | 9.987                     | 0.002   | 1.01     | (1.001, 1.006) |
| BUN                 | 0.127  | 0.071 | 3.160                     | 0.075   | 1.14     | (0.987, 1.305) |
| mALB                | 0.013  | 0.009 | 2.006                     | 0.157   | 1.013    | (0.995, 1.032) |
| Sex (Male)          | 0.630  | 0.253 | 6.217                     | 0.013   | 1.878    | (1.144, 3.083) |

TABLE 6 Multivariate Logistic regression analysis of early renal impairment (CysC>1.25mg/L) in hypertensive patients.

patients with early CKD and progressively worsens as the disease progresses to end-stage renal disease. IR may participate in the occurrence and development of CKD through such mechanisms as a hyperinsulinemic reaction (14), induction of oxidative stress (15), activation of a sympathetic renin-angiotensin-aldosterone system (16), activation of inflammatory factors (17), and inhibition of insulin signaling pathway (18). Cheng HT al (19). have found that IR plays an important role in the occurrence and development of renal lesions in chronic renal diseases, which is associated with a rapid decline in the prevalence and renal function of CKD.

Microalbuminuria is an early manifestation of hypertensive renal injury and can be used as an early indication of renal injury (20). Urinary microalbumin cannot pass the glomerular





10.3389/fendo.2022.1038758

filtration membrane under physiological conditions, and its content is extremely low. When the glomerulus is damaged, the protein filtration barrier will be damaged, with increased permeability and excretion of microalbumin in urine. Hence, microalbuminuria is one of the sensitive indicators of early glomerular injury (21). However, the random urine test has mixed influencing factors, such as urine concentration and exercise, which can affect its test results, resulting in poor applicability of clinical diagnosis. In addition, BUN and SCr are widely used clinically to evaluate renal function. However, due to the strong renal storage capacity, as well as the influence of drugs, age, glomerular filtration rate and other factors, significant abnormalities only appear in severe renal impairment, and its diagnostic specificity is low in the early stage of renal impairment. Therefore, in this study, the correlation between the TyG index and markers of renal disease such as mAlb, eGRF and BUN was small. CysC is a cysteine protease inhibitor, produced by nucleated cells. This molecule is widely present in tissues throughout the body and is produced at a constant rate (22). The kidney is the only organ of CysC clearance and the glomerular filtration rate determines its concentration in the serum. Therefore, CysC is a sensitive indicator reflecting the glomerular filtration rate (23). The previous study has found that the sensitivity and specificity of CysC in the diagnosis of kidney injury were superior to those of creatinine and urea nitrogen, and it had higher sensitivity and stronger specificity, which gradually increased with the aggravation of the disease (24). Meanwhile, Khan et al. (25) studied 300 patients with CKD aged ≥65 and found that CysC was not related to body mass index and age of patients, and CysC had better performance than serum creatinine in assessing the renal function of patients, which is consistent with the results of this study.  $\beta$ 2-MG is a small molecular protein with low content in the body, but the concentration remains constant.  $\beta$ 2-MG is excreted through the glomerular filtration membrane, and decreased glomerular filtration rate can lead to increased B2-MG level, suggesting impairment of renal function. Studies have confirmed that the abnormal rate of  $\beta$ 2-MG reaches 42.07% when the serum creatinine is increased by 0.7%, which is a sensitive indicator of early lesions in hypertensive kidney injury (26).

IR is an underlying condition for hypertension onset (27). The current gold standard for IR measurement is the normal blood glucose clamp test. However, due to the time-consuming, expensive, and complex nature of glucose clamp testing, it is difficult to apply in large-population research and clinical settings. Guerrero-Romero et al. (7) investigated a TyG index derived from fasting triglyceride and glucose concentrations as an IR index and validated it against the normoglycemic clamp test in a Mexican population, showing its superiority over HOMA-IR. Studies have confirmed that the TyG index predicts the development of hypertension in Chinese populations (28) and may reflect cardiac remodeling,

dysfunction, and atherosclerosis (29). KHAN et al. (30) found a high positive correlation between the TyG index and urine albumin creatine ratio in a cross-sectional study that included 227 patients with metabolic syndrome. Fritz et al. (31) found that the TyG index appeared to be associated with ESKD risk and mediates nearly half of the total association between BMI and ESKD in the general population. This study was the first to explore the relationship between the TyG index and early renal impairment in hypertensive patients. Because of the special geographical location of our hospital in the northwest plateau, we have a medical center for hypertension, so our study mainly included patients whose blood pressure was unstable at an early stage, and who did not have heart disease, tumors, etc. This is the advantage of our study, which can better assess the relationship between the TYG index and early renal function in hypertensive patients. The results showed that markers of early renal impairment such as serum β2-MG and CysC in the H-TyG index group were significantly higher than those in the M-TyG group and L-TyG group, and the level in the M-TyG group was also higher than that in the L-TyG group. However, the results of this study showed that the TyG index was not related to urinary microalbumin, which could be affected by several confounding factors. In addition, β2-MG>2.4 mg/L and CysC>1.25 mg/L in serum were considered as the early stage of renal impairment. All the results have shown that the TyG index level in the renal impairment group was significantly higher than that in the normal renal function group. The results of the ROC curve analysis showed that the TyG index had some value in predicting early renal impairment in hypertensive patients, but was not superior to TG alone. TyG index is the product index of TG and FBG, which is respectively an index of blood glucose and lipid metabolism, reflecting well the fat toxicity and sugar toxicity playing very important roles in Diabetic Kidney Disease.

# **Study limitations**

This study has certain limitations. First, results were obtained from a retrospective study, and selection bias was inevitable. Second, we only measured fasting triglycerides and fasting plasma glucose levels at admission; these parameters were not measured continuously. Third, we can only prove the correlation between the TyG index and early renal impairment in patients with hypertension, but whether they have a causal relationship requires further prospective studies.

### Conclusion

TyG index is an influential factor in serum  $\beta$ 2-MG and CysC levels. The elevated TyG index levels are closely associated with the occurrence and development of early renal impairment in hypertensive patients, but it should be used cautiously in the

prediction of early renal impairment. Therefore, for hypertensive patients, to protect target organ function, the treatment of IR should be paid attention to delay the occurrence of renal damage while strictly controlling blood pressure to reach the standard.

### Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

### **Ethics statement**

The studies involving human participants were reviewed and approved by Qinghai Provincial People's Hospital. The patients/ participants provided their written informed consent to participate in this study.

### Author contributions

JD and HY: Data collection, analyses and interpretation, and writing of the final manuscript. JD, HY, YZ, LC, and QH: Study

# References

1. Lotfaliany M, Akbarpour S, Mozafary A, Boloukat R, Azizi F, Hadaegh F. Hypertension phenotypes and incident cardiovascular disease and mortality events in a decade follow-up of a middle East cohort. *J hypertens* (2015) 33(6):1153–61. doi: 10.1097/hjh.0000000000540

2. Meng L, Yang Y, Qi L, Wang X, Xu G, Zhang B. Elevated serum cystatin c is an independent predictor of cardiovascular events in people with relatively normal renal function. *J Nephrol* (2012) 25(3):426–30. doi: 10.5301/jn.5000020

3. Bevc S, Hojs N, Knehtl M, Ekart R, Hojs R. Cystatin c as a predictor of mortality in elderly patients with chronic kidney disease. *Aging male: Off J Int Soc Study Aging Male* (2019) 22(1):62–7. doi: 10.1080/13685538.2018.1479386

4. Tessari P, Cecchet D, Vettore M, Coracina A, Puricelli L, Kiwanuka E. Decreased homocysteine trans-sulfuration in hypertension with hyperhomocysteinemia: Relationship with insulin resistance. *J Clin Endocrinol Metab* (2018) 103(1):56–63. doi: 10.1210/jc.2017-01076

5. Artunc F, Schleicher E, Weigert C, Fritsche A, Stefan N, Häring H. The impact of insulin resistance on the kidney and vasculature. *Nat Rev Nephrol* (2016) 12(12):721–37. doi: 10.1038/nrneph.2016.145

6. Guerrero-Romero F, Villalobos-Molina R, Jiménez-Flores J, Simental-Mendia L, Méndez-Cruz R, Murguía-Romero M, et al. Fasting triglycerides and glucose index as a diagnostic test for insulin resistance in young adults. *Arch Med Res* (2016) 47(5):382–7. doi: 10.1016/j.arcmed.2016.08.012

7. Guerrero-Romero F, Simental-Mendía L, González-Ortiz M, Martínez-Abundis E, Ramos-Zavala M, Hernández-González S, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. comparison with the euglycemic-hyperinsulinemic clamp. *J Clin Endocrinol Metab* (2010) 95 (7):3347–51. doi: 10.1210/jc.2010-0288

8. Mao Q, Zhou D, Li Y, Wang Y, Xu S-C, Zhao X-H. The triglyceride-glucose index predicts coronary artery disease severity and cardiovascular outcomes in patients with non-ST-Segment elevation acute coronary syndrome. *Dis Markers* (2019) 2019(1–11): 6891537. doi: 10.1155/2019/6891537

design, Data interpretation, and revising the manuscript. All authors contributed to the article and approved the submitted version.

### Funding

This research was supported by Qinghai Science and Technology Program Fund, with the project number (2019ZJ7051).

# Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

9. Wang Y, Yang W, Jiang X. Association between triglyceride-glucose index and hypertension: A meta-analysis. *Front Cardiovasc Med* (2021) 8:644035 (644035). doi: 10.3389/fcvm.2021.644035

10. Li X, Li G, Cheng T, Liu J, Song G, Ma H. Association between triglycerideglucose index and risk of incident diabetes: a secondary analysis based on a Chinese cohort study: TyG index and incident diabetes. *Lipids Health Dis* (2020) 19(1):236. doi: 10.1186/s12944-020-01403-7

11. Lv L, Zhou Y, Chen X, Gong L, Wu J, Luo W, et al. Relationship between the TyG index and diabetic kidney disease in patients with type-2 diabetes mellitus. *Diabetes Metab syndr obesity: Targets Ther* (2021) 14:3299–06. doi: 10.2147/ dmso.S318255

12. Zhang S, Du T, Zhang J, Lu H, Lin X, Xie J, et al. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. *Lipids Health Dis* (2017) 16(1):15. doi: 10.1186/s12944-017-0409-6

13. Zhao S, Yu S, Chi C, Fan X, Tang J, Ji H, et al. Association between macroand microvascular damage and the triglyceride glucose index in communitydwelling elderly individuals: the northern shanghai study. *Cardiovasc Diabetol* (2019) 18(1):95. doi: 10.1186/s12933-019-0898-x

14. Lindblad Y, Axelsson J, Bárány P, Celsi G, Lindholm B, Qureshi A, et al. Hyperinsulinemia and insulin resistance, early cardiovascular risk factors in children with chronic kidney disease. *Blood purif* (2008) 26(6):518–25. doi: 10.1159/000167799

15. Wang C, Blough E, Arvapalli R, Dai X, Paturi S, Manne N, et al. Metabolic syndrome-induced tubulointerstitial injury: role of oxidative stress and preventive effects of acetaminophen. *Free Radical Biol Med* (2013) 65:1417–26. doi: 10.1016/j.freeradbiomed.2013.10.005

16. Thethi T, Kamiyama M, Kobori H. The link between the renin-angiotensinaldosterone system and renal injury in obesity and the metabolic syndrome. *Curr hypertens Rep* (2012) 14(2):160–9. doi: 10.1007/s11906-012-0245-z 17. Shimobayashi M, Albert V, Woelnerhanssen B, Frei I, Weissenberger D, Meyer-Gerspach A, et al. Insulin resistance causes inflammation in adipose tissue. J Clin Invest (2018) 128(4):1538–50. doi: 10.1172/jci96139

18. Manrique C, Lastra G, Gardner M, Sowers J. The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. *Med Clinics North America* (2009) 93(3):569-82. doi: 10.1016/j.mcna.2009.02.014

19. Cheng H, Huang J, Chiang C, Yen C, Hung K, Wu K. Metabolic syndrome and insulin resistance as risk factors for development of chronic kidney disease and rapid decline in renal function in elderly. *J Clin Endocrinol Metab* (2012) 97 (4):1268–76. doi: 10.1210/jc.2011-2658

20. Oz-Sig O, Kara O, Erdogan H. Microalbuminuria and serum cystatin c in prediction of early-renal insufficiency in children with obesity. *Indian J Pediatr* (2020) 87(12):1009–13. doi: 10.1007/s12098-020-03294-z

21. Rosner M, Bolton W. Renal function testing. Am J Kidney Dis (2006) 47 (1):174–83. doi: 10.1053/j.ajkd.2005.08.038

22. Zhang Y, Sun L. Cystatin c in cerebrovascular disorders. *Curr neurovascular Res* (2017) 14(4):406–14. doi: 10.2174/1567202614666171116102504

23. Onopiuk A, Tokarzewicz A, Gorodkiewicz E. Cystatin C: A kidney function biomarker. *Advances in clinical chemistry* (2015) 68:57–69. doi: 10.1016/ bs.acc.2014.11.007

24. Pavkov M, Knowler W, Hanson R, Williams D, Lemley K, Myers B, et al. Comparison of serum cystatin c, serum creatinine, measured GFR, and estimated GFR to assess the risk of kidney failure in American indians with diabetic nephropathy. *Am J Kidney dis: Off J Natl Kidney Found* (2013) 62(1):33–41. doi: 10.1053/j.ajkd.2012.11.044

25. Khan I, Khan A, Adnan A, Sulaiman S, Hamzah A, Ahmed N, et al. Effect of socio-demographic factors on endogenous biomarkers (cystatin c and creatinine) among elderly chronic kidney disease patients: a cross-sectional study. *Int Urol Nephrol* (2018) 50(6):1113–21. doi: 10.1007/s11255-018-1834-9

26. Shirzai A, Yildiz N, Biyikli N, Ustunsoy S, Benzer M, Alpay H. Is microalbuminuria a risk factor for hypertension in children with solitary kidney? *Pediatr Nephrol (Berlin Germany)* (2014) 29(2):283–8. doi: 10.1007/s00467-013-2641-2

27. da Silva A, do Carmo J, Li X, Wang Z, Mouton A, Hall J. Role of hyperinsulinemia and insulin resistance in hypertension: Metabolic syndrome revisited. *Can J Cardiol* (2020) 36(5):671-82. doi: 10.1016/j.cjca.2020.02.066

28. Yang K, Liu W. Triglyceride and glucose index and sex differences in relation to majo r adverse cardiovascular events in hypertensive patients without diabe tes. *Front Endocrinol (Lausanne)* (2021) 12:761397(761397). doi: 10.3389/ fendo.2021.761397

29. Chiu T, Tsai H, Chiou H, Wu P, Huang J, Chen S. A high triglycerideglucose index is associated with left ventricular dysfunction and atherosclerosis. *Int J Med Sci* (2021) 18(4):1051–7. doi: 10.7150/ijms.53920

30. Khan S, Sobia F, Niazi N, Manzoor S, Fazal N, Ahmad F. Metabolic clustering of risk factors: evaluation of triglyceride-glucose index (TyG index) for evaluation of insulin resistance. *Diabetol Metab syndr* (2018) 10:74. doi: 10.1186/s13098-018-0376-8

31. Fritz J, Brozek W, Concin H, Nagel G, Kerschbaum J, Lhotta K, et al. The triglyceride-glucose index and obesity-related risk of end-stage kidney disease in Austrian adults. *JAMA netw Open* (2021) 4(3):e212612. doi: 10.1001/jamanetworkopen.2021.2612